Should You Buy Clover Health Investments Corp (CLOV) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
Not a good buy right now for a beginner long-term investor with $50k–$100k. CLOV is in a clear bearish trend (below key moving averages with weakening momentum) and the near-term news flow is negative for Medicare Advantage profitability. While the stock looks oversold and fundamentals show strong revenue growth with improving losses, the current setup is still “falling knife” risk rather than a stable long-term entry. If you already own it, this is not a favorable add-point; if you don’t, avoid initiating now.
Technical Analysis
Trend is bearish: SMA_200 > SMA_20 > SMA_5 confirms a sustained downtrend. Momentum is weakening further with MACD histogram at -0.0257 and negatively expanding. RSI(6) ~27 suggests the stock is oversold (bounce potential), but oversold in a downtrend is not a reliable long-term entry signal. Key levels: near support S1=2.352 and S2=2.212 (price 2.31 is below S1), with resistance/pivot around 2.577 and R1=2.802. A durable reversal would typically require reclaiming the pivot (2.577) and improving MACD/RSI—neither is present.
Analyst Ratings and Price Target Trends
Analyst trend: Canaccord maintained a Buy rating (2025-11-06) but lowered the price target from $4.10 to $3.70 after a 3Q adjusted EBITDA miss and reduced profitability guidance tied to elevated medical cost trends and prior period development. Wall Street pros: strong membership/revenue growth and a potential multi-year turnaround if costs normalize. Cons: Medicare Advantage margin sensitivity (medical cost trend + reimbursement outlook), guidance credibility after revisions, and a weak technical backdrop that suggests the market is still de-risking.
Influential/political trading: No recent congress trading data available; hedge funds and insiders show neutral activity with no significant recent trends.
Wall Street analysts forecast CLOV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLOV is 3.35 USD with a low forecast of 3 USD and a high forecast of 3.7 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast CLOV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLOV is 3.35 USD with a low forecast of 3 USD and a high forecast of 3.7 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 2.310
Current: 2.310
